We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Microfluidic Device Monitors Key Step in Development of Tumor Metastases

By LabMedica International staff writers
Posted on 03 Sep 2014
A device has been developed that may help study key steps in the process by which cancer cells break off from a primary tumor to invade other tissues and form metastases.

The microfluidic device described as an EMT chip, where EMT stands for epithelial-mesenchymal transition, reveals a fundamental change in cellular characteristics that has been associated with the ability of tumor cells to migrate and invade other sites in the body. More...
Therapies that target this process may be able to slow or halt tumor metastasis.

Bioengineers at Massachusetts General Hospital (Boston, MA, USA) who developed the device allows investigators to follow the movement of cells passing through a comb-like array of micropillars, which temporarily separates cells that are adhering to each other. To establish baseline characteristics of noncancerous cells, the investigators first studied the passage of normal epithelial cells through the array. They observed that those cells moved at the same speed as neighboring cells, reconnecting when they come into contact with each other into multicellular sheets that repeatedly break apart and reseal. Tumor cells, however, passed quickly and more directly through the device and did not interact with nearby cells.

When cells in which the process of EMT had been initiated by genetic manipulation were observed passing through the device, at first they migrated collectively, but soon after encountering the first micropillars, many cells broke away from the collective front and migrated individually for the rest of their trajectory. Some cells appeared to undergo the opposite transition, reverting from individual migration back to collective migration. Subsequent analysis revealed that the slower moving cells that continued migrating together expressed epithelial markers, while the faster moving, independently migrating cells expressed mesenchymal markers. The individually cells migrating also appeared to be more resistant to treatment with chemotherapy drugs.

Daniel Irimia, MD, PhD, an assistant professor of Surgery and the senior author of the study, said, “This device gives us a platform to be used in testing and comparing compounds to block or delay the epithelial-mesenchymal transition, potentially slowing the progression of cancer. Instead of providing a snapshot of cells or tissues at a specific moment, as traditional histology studies do, the new chip can capture the changing dynamics of individual or collective cellular migration.” The study was published on August 17, 2104, in the journal Nature Materials.

Related Links:

Massachusetts General Hospital



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Pipette Calibration System
Artel PCS®
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.